Granules India gets USFDA’s approval for Metoprolol Succinate ER Tablets

13 Jun 2023 Evaluate

Granules India has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Metoprolol Succinate Extended-Release Tablets USP, 25 mg, 50 mg, 100 mg and 200 mg. It is bioequivalent to the reference listed drug product (RLD), Toprol-XL Tablets, 25 mg, 50 mg, 100 mg and 200 mg, of Toprol Acquisition LLC.

Metoprolol Succinate ER Tablets are indicated for the treatment of hypertension in order to lower blood pressure.  Granules now has a total of 57 ANDA approvals from USFDA (55 final approvals and 2 tentative approvals). The current annual U.S. market for Metoprolol Succinate ER Tablets is approximately $321 million, according to MAT March 2023, IQVIA/IMS Health.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

594.05 13.20 (2.27%)
11-Mar-2026 10:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1832.70
Dr. Reddys Lab 1330.40
Cipla 1331.50
Zydus Lifesciences 933.00
Lupin 2369.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×